Articles tagged with Hormone Therapy
The phase 3 KATHERINE clinical trial found trastuzumab emtansine to be an effective adjuvant treatment for high-risk HER2-positive breast cancer patients, reducing the risk of death or invasive disease by 46% and improving survival. The study showed consistent benefits across patient subgroups, supporting T-DM1 as a new standard of care.
A new large-scale study published in Menopause found no significant association between hormone therapy use and risk of glioma, a common brain cancer. Women are still six times more likely to develop gliomas than men.
The study found that Jinfeng pill treatment improved ovarian size, follicle development, and hormone levels in POR rat model. The combination therapy produced the most significant improvements, including increased VEGF expression and balanced hormones.
A new study by UCSF found that menopause increases the rate of MS progression in women, particularly in walking speed and fine motor skills. The study also suggests that hormone therapy may be beneficial in slowing disease progression, with some participants showing a lower rate of relapse during pregnancy.
A new study from Harvard T.H. Chan School of Public Health and colleagues reveals that less than 0.1% of privately insured US adolescents receive puberty blockers or gender-affirming hormones. No TGD patients under age 12 were prescribed hormone treatment, indicating low access to care among this population.
A new study found that nearly half of high-risk prostate cancer patients have metastatic disease when evaluated with advanced PSMA-PET imaging, suggesting traditional imaging may underestimate cancer spread. This challenge the interpretation of previous studies like EMBARK trial, and support the inclusion of PSMA-PET for patient select...
Menopausal women in rural areas reported more mood swings, muscle and joint pain, vaginal dryness, and urinary problems than their urban counterparts. Many respondents did not receive hormone replacement therapy due to fear of risks or lack of education about the treatment option.
A preclinical study led by Weill Cornell Medicine scientists found that estrogen surges promote binge drinking in females, causing them to 'pregame' and consume large quantities of alcohol. The study identifies a neural circuit in the brain where estrogen increases activity, leading to enhanced binge drinking behavior.
Researchers are discovering selenium nanoparticles' potential in cancer prevention, inflammation reduction, and tumor treatment through their ability to activate the immune system and reduce inflammation. SeNPs are also being explored as vaccine adjuvants to improve immune cell activation and boost cancer vaccine efficacy.
The European Society of Endocrinology (ESE) and ESE Foundation will host the first-ever World Hormone Day on April 24, 2025. The campaign aims to raise public awareness of good hormone health and improve national political engagement for better prevention, diagnosis, and treatment of endocrine disease.
The study demonstrated a median progression-free survival of 18.2 months and a disease control rate of 97.5% among participants with hormone receptor-positive and HER2-positive metastatic breast cancer. The combination treatment was well-tolerated, with no grade 4 adverse events reported.
Researchers found that neuroinflammation in the hippocampus significantly alters motivation and behaviour in mice, particularly in females. This study suggests that treatments targeting hippocampal neuroinflammation could help reduce cognitive and behavioural symptoms in diseases such as Alzheimer's and Depression.
Researchers found that flavonoids in everyday foods like green tea and dark chocolate regulate glucose levels through gut receptors, paving the way for better health management. The study highlights the potential of polyphenol-rich diets to improve public health and offers a foundation for developing new therapies.
For patients with 'good-risk' ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the same breast. The estimated 15-year risk of ipsilateral recurrence was 11.4% for patients treated with tamoxifen.
The EMBER-3 clinical trial showed that imlunestrant improved progression-free survival in patients with ER-positive, HER2-negative advanced breast cancer, particularly those with ESR1 mutations. The combination of imlunestrant and abemaciclib also demonstrated a significant reduction in risk of progression or death.
Researchers at UCLA Health presented several breakthroughs at the San Antonio Breast Cancer Symposium, including improved survival rates for advanced breast cancer patients who receive trastuzumab deruxtecan (T-DXd), a novel ADC. Additionally, new genomic testing and circulating tumor DNA analysis may help identify high-risk patients a...
A Brazilian researcher at Harvard identified serotonin as the central role in postprandial hypoglycemia, a common complication of bariatric surgery. The study found that serotonin levels increase significantly after meals in affected individuals, unlike those without symptoms.
The new guidelines provide 145 recommendations on symptoms, diagnosis, causation, sequelae, and treatment of POI. They emphasize personalized hormone therapy, prompt institution, and continuation until the usual age of menopause to prevent chronic disease and improve patient outcomes.
Researchers found that women who had both ovaries surgically removed before age 50 are at high risk of late-life Alzheimer's disease, with a fourfold increase in risk linked to the APOE4 allele. Hormone therapy reduces this risk by half in these women.
Researchers have identified structural grey matter differences in the brains of women with a history of peripartum depression compared to those without. The study found that hormone fluctuations during pregnancy and childbirth may be key to understanding this condition.
The landmark review charts the transformation of pituitary tumor treatment from early hormone regulation experiments to modern precision therapies. Key findings include significant advances in prolactinoma and acromegaly treatments, as well as emerging areas for research like receptor modulators and immunotherapy.
Dr. Seymour Reichlin's centennial celebration highlights his ongoing scientific impact, with recent collaborations yielding new insights into hormone therapies for cognitive enhancement and emotional homeostasis. His work has established neuroendocrinology as a distinct field, bridging neuroscience, endocrinology, and clinical medicine.
The American Heart Association warns hunters about the increased risk of heart attack and stroke due to exertion, cold temperatures, and excitement. Hunters should recognize symptoms, take breaks, and have a plan in case of emergencies. Learning Hands-Only-CPR can also save lives.
A study found that postmenopausal women with low-risk tumors experience a long-term benefit from anti-hormonal treatment of at least 20 years, while younger women do not. The researchers highlight the need for new markers to predict long-term risk and benefit in younger patients.
Long-term hormone therapy in transgender individuals leads to significant changes in body composition and risk factors for cardiovascular disease. Transgender men experience increased muscle volume and abdominal fat, while women's muscle mass decreases, according to a new study published in the Journal of Internal Medicine.
Research finds that hormone replacement therapy (HRT) containing oestrogen and progestogen increases the risk of heart disease and blood clots, while tibolone has a similar effect on heart attack and stroke. Transdermal HRT treatments show no increased risk.
Researchers analyzed the effects of seven hormone treatments on blood clots, stroke, and heart attack in nearly one million women. The study shows that the risks differ depending on the type of treatment, with some linked to increased cardiovascular disease risk and others to no increased risk.
A new study led by Weill Cornell Medicine found that tirzepatide reduced the risk of diabetes in obese and prediabetic patients by more than 90% after 176 weeks. The treatment also showed significant weight loss and improved blood sugar control.
Researchers at the University of Vienna have developed a new class of oral peptide therapeutic leads for treating chronic abdominal pain. These gut-stable oxytocin analogues offer a safe, non-opioid-based solution for conditions such as IBS and IBD.
Researchers found that short-term MHT did not cause long-term cognitive decline in women in early postmenopause. The KEEPS Continuation Study suggests that timing is crucial for the safety of MHT.
Research found that spironolactone reduced the likelihood of heart failure after a heart attack, but did not significantly reduce deaths or other severe heart-related events. The study included over 7,000 adults in 14 countries who had experienced a severe heart attack.
New research reveals that hormone therapy can alter skeletal size and shape in transgender individuals who previously suppressed puberty. Transgender men treated with puberty blockers and hormone therapy have broader shoulders and a smaller pelvic inlet, while women have a larger pelvis after treatment from early puberty.
Scientists have discovered a new weight loss drug target that increases calorie-burning and lowers appetite without causing nausea. The discovery could lead to a new therapy for millions of people with obesity and type 2 diabetes.
Researchers have discovered a new strategy to overcome docetaxel resistance in advanced prostate cancer patients, which may improve the efficacy of chemotherapy and prolong overall survival. The approach involves inhibiting cholesterol and lipid biosynthesis, reinducing sensitivity to the drug docetaxel.
Boston Medical Center and Boston University researchers have made a breakthrough in developing cell-based therapy for hypothyroidism. They derived transplantable thyroid follicular epithelial cells from human induced pluripotent stem cells, which can be transplanted into thyroid-deficient animal models.
Researchers at Mayo Clinic recommend minimally invasive treatment alternatives to hysterectomy for uterine fibroids, which can help women recover faster and reduce long-term risks. Early detection and treatment are key in reducing health disparities among Black women.
A new study has found that Canadian women who did not identify as White have an earlier peak age of breast cancer diagnosis and higher proportions of cases diagnosed under age 50. They also experience an earlier peak age of death, with a 7-year gap in mortality rates compared to their White counterparts.
A WHO guideline panel is under fire for lacking transparency and association with WPATH, which supports 'gender affirming' approach. The controversy raises questions about the evidence-based nature of the recommendations.
Researchers have unveiled a complex interplay between liver X and thyroid hormone receptors that regulates critical brain functions and protects against neurodegeneration. LXRs play a crucial role in regulating thyroid hormone function in the brain, while both receptors are essential for normal brain development and maintenance.
A UK study found that menopausal hormone therapy may have moderate effects on brain health, but these depend on past surgical history, treatment duration, and age at last use. The research revealed no significant differences in brain health between women who used MHT and those who did not, but those on MHT had higher grey and white-mat...
The latest APA journal issues explore schizophrenia spectrum disorders, PTSD treatment, and college mental health. Research highlights include new approaches to psychosis treatment and findings on mental health in higher education.
A Duke-NUS study proposes a new treatment for heart failure with preserved ejection fraction (HFpEF) by blocking glucagon's activity, which raises blood sugar levels. This breakthrough could provide quicker relief to millions of heart patients.
A cross-sectional study found that menopausal hormone therapy use has decreased significantly over the past two decades among US postmenopausal women. Notably, women from racial and ethnic minority groups had lower rates of menopausal hormone therapy use compared to non-Hispanic white women.
Early-stage HR+ breast cancer survivors experience weight gain, particularly those with healthy BMI or overweight at diagnosis. Black women have higher rates of obesity and related comorbidities compared to White women, leading to a 40% higher breast cancer mortality rate.
Researchers have provided compelling evidence that perceived stress can directly trigger the relapse of psoriatic skin lesions. The study used a humanized mouse model to show that sonic stress led to a relapse in all psoriasis lesions within 14 days, accompanied by increased inflammation and immune activation.
According to the Global Cancer Observatory (GLOBOCAN), lung cancer is the most common type of cancer, with 2.2 million new cases and 1.8 million deaths worldwide in 2020. China had the highest number of new cases, and incidence and mortality rates have been steadily rising from 1990 to 2019.
A large study found that women with premature ovarian insufficiency are 2.6 times more likely to have an autoimmune disorder, with some conditions increasing the risk by 26 times. The study suggests a strong link between POI and severe autoimmune diseases, highlighting the need for medical professionals to be aware of this increased risk.
A new study has found that baseline testosterone, age, and duration of ADT are key predictors of testosterone recovery. The researchers developed a nomogram to estimate recovery times based on patient-specific characteristics, providing valuable insights for improving patient outcomes.
A study found that Black women with breast cancer are more likely to experience vaginal dryness, reduced libido, and painful intercourse, leading to lower mental quality of life. These symptoms were associated with decreased adherence to treatment in these patients.
New study finds that extended estrogen suppression using aromatase inhibitors for hormone receptor-positive postmenopausal breast cancer is safe and does not increase the risk of coronary artery calcification. The duration of treatment and presence of osteoporosis were not associated with increased coronary artery calcification scores.
Researchers discovered a novel treatment that extends ovarian function in older mice by improving maintenance of the ovaries and preventing key age-related changes. The treatment also fixes hormone production and overall health, alleviating symptoms such as bone loss, cardiovascular disease, and cognitive decline.
A retrospective analysis of over 100 women aged 65+ found that many continued to experience benefits from hormone therapy, with hot flashes being the primary reason for continued use. The study suggests that healthcare professionals should consider individual risk factors and health status when deciding on hormone therapy for older women.
A new study confirms that hormone therapy is still underutilized among women over 65, with only 70-80% experiencing menopause symptoms. The majority of participants continued hormone therapy to manage hot flashes and improve their quality of life, highlighting the need for more open consideration of its use in this age group.
A new study based on Women's Health Initiative data suggests that certain estrogen-based hormone therapies may have a beneficial impact on cardiovascular biomarkers, except for triglycerides. The study found significant improvements in HDL-C and LDL-C levels, as well as reductions in insulin resistance and lipoprotein(a) levels.
The September issues of APA journals focus on depression risk factors and treatments, as well as noninvasive brain stimulation therapies. The American Journal of Psychiatry explores the promise of these therapies in treating depression.
Postmenopausal women who received hormone therapy were biologically younger than those who did not, with a stronger association observed in low-income individuals. The study suggests that promoting hormone therapy could be essential for healthy aging and reducing mortality rates.
Researchers investigated the connection between androgen deprivation therapy for prostate cancer and Alzheimer's disease. They found that ADT can exacerbate cognitive decline by increasing brain immune cell infiltration, but a combination with Natalizumab improved integrity of the blood-brain barrier and reduced inflammation.
A phase II clinical trial found that olaparib, a precision oncology drug, can induce durable complete remissions in recurrent prostate cancer patients with BRCA2 mutations. The study showed that 13 participants, including all 11 with BRCA2 mutations, had a decrease in PSA of at least 50% after treatment.
A new non-hormonal hot flash treatment has been shown to significantly reduce symptom frequency and severity within weeks, while also improving sleep quality and overall well-being. The investigational drug elinzanetant was found to have a favorable safety profile with mild side effects.
A new study published in Nature Medicine shows that precision therapy can improve survival for men with metastatic castration-resistant prostate cancer. The treatment, which involves analyzing the genetic profile of the tumor, has been shown to be more effective than chemotherapy in patients whose tumors have specific mutations.